The Third Survey of Prescription Pattern of Psychotropic Drugs in China

August 17, 2012 updated by: Si Tianmei, Peking University

The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder

The investigators aimed to examine the psychotropic prescription pattern in China.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

7000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100191
        • Recruiting
        • Institute of Mental Health, Peking University
        • Contact:
        • Principal Investigator:
          • Tianmei Si, PhD.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

schizophrenia, depression and bipolar disorder patients

Description

Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged<18or aged>65

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Beijing region
include six hospitals
Guangdong Province
include 3 hospitals
Jiangsu province
include 3 hospitals
Hebei province
include 6 hospitals
Hubei Province
include 7 hospitals
Shanxi province
include 3 hospitals
Jiangxi province
include 3 hospitals
Jilin province
include 6 hospitals
Sichuan province
include 3 hospitals
Shaanxi province
include 3 hospitals

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University

Collaborators

Xian-Janssen Pharmaceutical Ltd.

Investigators

  • Study Chair: Xin Yu, MD., Peking University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Anticipated)

September 1, 2012

Study Completion (Anticipated)

July 1, 2013

Study Registration Dates

First Submitted

August 16, 2012

First Submitted That Met QC Criteria

August 17, 2012

First Posted (Estimate)

August 20, 2012

Study Record Updates

Last Update Posted (Estimate)

August 20, 2012

Last Update Submitted That Met QC Criteria

August 17, 2012

Last Verified

July 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RISSCH4255

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prescription

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe